Nessan Bermingham, Triplet Therapeutics CEO
October 12, 2022 10:01 AM EDT
R&D

At­las-backed biotech fo­cused on Hunt­ing­ton's dis­ease shuts down less than three years af­ter launch

Max Gelman

Senior Editor

An At­las-found­ed biotech qui­et­ly shut down this week, with the CEO post­ing on­ly a short state­ment on LinkedIn to an­nounce the move.

Triplet Ther­a­peu­tics is …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

A service from the Financial Times